Company / Capital Expenditures
SAB Biotherapeutics, Inc. Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$337.3K
FY2025
5-year range
$197.2K / $12.7M
FY2021-FY2025
Trend
+71.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures returned to growth in FY2025 after 3 years of decline, reaching $337,262.
Based on SEC 10-K filings.
$337,262 in FY2025 with a 3-year CAGR of -68.6%.
Declined from $2M to $337,262 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -68.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -68.6%, indicating a declining trend.
- In FY2025, capital expenditures increased 71.1% year-over-year.
- Peak capital expenditures was recorded in FY2021.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $337.3K | +71.1% |
| FY2024 | $197.2K | -90.9% |
| FY2023 | $2.2M | -80.2% |
| FY2022 | $10.9M | -14.0% |
| FY2021 | $12.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026